Peter is an experienced life-science industry executive with over forty years’ experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales representative to country-level general manager and CEO and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs in the vaccine/biologics and specialty pharmaceutical sectors. At Glaxo Wellcome in the mid-1990s he led the global introduction of combination HIV therapy while keying industry leadership on global treatment access.
Currently Peter serves as a senior venture partner with Pappas Capital, where he leads the firm’s initiatives in translational medicine and is the Program Manager for Wake Forest Baptist Medical Center’s Technology Development Program. He also serves as an Executive in Residence at Cold Spring Harbor Laboratories and the Center for Biotechnology at Stony Brook University, and as a Mentor in Residence in Rutgers’ Health Advance program, as well as on the board of directors of several start-up life science companies. He is a member of the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, the Long Island Bioscience Hub External Review Board and the Long Island BioMentor Initiative, the Scientific Advisory Board of New York’s Empire Discovery Institute, a member of Washington University’s Therapeutics Domain Expert Program, a past member of the BIO board and chairman of the North Carolina Biosciences Organization, and a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009.
Currently Peter serves as a senior venture partner with Pappas Capital, where he leads the firm’s initiatives in translational medicine and is the Program Manager for Wake Forest Baptist Medical Center’s Technology Development Program. He also serves as an Executive in Residence at Cold Spring Harbor Laboratories and the Center for Biotechnology at Stony Brook University, and as a Mentor in Residence in Rutgers’ Health Advance program, as well as on the board of directors of several start-up life science companies. He is a member of the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, the Long Island Bioscience Hub External Review Board and the Long Island BioMentor Initiative, the Scientific Advisory Board of New York’s Empire Discovery Institute, a member of Washington University’s Therapeutics Domain Expert Program, a past member of the BIO board and chairman of the North Carolina Biosciences Organization, and a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009.
Speaking In
11:00 AM - 12:00 PM
Wednesday, June 7
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
